Differential Impact of Class I and Class II Panel Reactive Antibodies on Post-Heart Transplant Outcomes

Patients with preformed antibodies against Human Leukocyte Antigens (HLA) wait longer for a transplant, have higher mortality on the waitlist and worse overall prognosis [1, 2]. There however remains some doubt regarding the impact of elevated pre-transplant panel reactive antibody activity (PRA) on post-transplant risk of rejection and survival [3, 4]. Historically, a PRA value greater than 25% was shown to be associated with decreased long-term survival based on data from both single center and larger UNOS/OPTN registry analysis [1, 3].

Source: Journal of Cardiac Failure - July 31, 2020 Category: Cardiology Authors: Juan B. Ivey-Miranda, Steffne Kunnirickal, Laurine Bow, Christopher Maulion, Jeffrey M. Testani, Daniel Jacoby, Evan P. Kransdorf, Lavanya Bellumkonda Source Type: research